Ameet Sarpatwari

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 33

Top Topics

Health Insurance

Psychometric Properties

Chronic Myeloid Leukemia

Top Venues

The New England journal of medicine

Annals of internal medicine

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Alexander C Egilman, Aaron S Kesselheim, Ameet Sarpatwari, Benjamin N Rome
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label. Annals of internal medicine 177 (6) (2024)
Ameet Sarpatwari, Zhigang Lu, Massimiliano Russo, Heidi Zakoul, Su Been Lee, Gita A Toyserkani, Esther H Zhou, Cynthia LaCivita, Katherine Hyatt Hawkins Shaw, Laura Zendel, Gerald J Dal Pan, Aaron S Kesselheim
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians. Clinical pharmacology and therapeutics (2024)
Alexander C Egilman, Aaron S Kesselheim, Ameet Sarpatwari, Benjamin N Rome
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label. Annals of internal medicine (2024)
Alexander C Egilman, Aaron S Kesselheim, Ameet Sarpatwari, Benjamin N Rome
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label. Annals of internal medicine 177 (6) (2024)
Ameet Sarpatwari, Zhigang Lu, Massimiliano Russo, Heidi Zakoul, Su Been Lee, Gita A Toyserkani, Esther H Zhou, Cynthia LaCivita, Katherine Hyatt Hawkins Shaw, Laura Zendel, Gerald J Dal Pan, Aaron S Kesselheim
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians. Clinical pharmacology and therapeutics 115 (6) (2024)
S Sean Tu, Ameet Sarpatwari
A "Method of Use" to Prevent Generic and Biosimilar Market Entry. The New England journal of medicine 388 (6) (2023)
Beatrice L Brown, Aaron S Kesselheim, Ameet Sarpatwari
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures. PLoS medicine 20 (3) (2023)
Catherine S Hwang, Aaron S Kesselheim, Ameet Sarpatwari, Krista F Huybrechts, Gregory Brill, Benjamin N Rome
Changes in Induced Medical and Procedural Abortion Rates in a Commercially Insured Population, 2018 to 2022 : An Interrupted Time-Series Analysis. Annals of internal medicine (2023)
Beatrice L Brown, Aaron S Kesselheim, Ameet Sarpatwari
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures. PLoS medicine 20 (3) (2023)
Ameet Sarpatwari, Beatrice L Brown, Sarah A McGraw, Sara Z Dejene, Abdurrahman Abdurrob, Aaron S Kesselheim
Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use. PloS one 18 (7) (2023)
S Sean Tu, Ameet Sarpatwari
A "Method of Use" to Prevent Generic and Biosimilar Market Entry. The New England journal of medicine 388 (6) (2023)
S Sean Tu, Ameet Sarpatwari
A "Method of Use" to Prevent Generic and Biosimilar Market Entry. The New England journal of medicine (2023)
C Joseph Ross Daval, Aaron S Kesselheim, Leigh Sharpless, Ameet Sarpatwari
Independent Advice on Drug Approvals: an Investigation of EMA Practices. Journal of general internal medicine (2023)
Beatrice L Brown, Aaron S Kesselheim, Ameet Sarpatwari
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures. PLoS medicine 20 (3) (2023)
S Sean Tu, Ameet Sarpatwari
A "Method of Use" to Prevent Generic and Biosimilar Market Entry. The New England journal of medicine 388 (6) (2023)
Patricia J Zettler, Ameet Sarpatwari
State Restrictions on Mifepristone Access - The Case for Federal Preemption. The New England journal of medicine 386 (8) (2022)
Bryan S Walsh, Aaron S Kesselheim, Ameet Sarpatwari, Benjamin N Rome
Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (10) (2022)
C Joseph Ross Daval, Aaron S Kesselheim, Ameet Sarpatwari
Improving the Use of FDA Advisory Committees. The New England journal of medicine 387 (8) (2022)
Victor L Van de Wiele, Reed F Beall, Aaron S Kesselheim, Ameet Sarpatwari
The characteristics of patents impacting availability of biosimilars. Nature biotechnology 40 (1) (2022)
Ameet Sarpatwari, Mayookha Mitra-Majumdar, Katsiaryna Bykov, Jerry Avorn, Steven Woloshin, Gita A Toyserkani, Cynthia LaCivita, Claudia Manzo, Esther H Zhou, Ellen Pinnow, Gerald J Dal Pan, Joshua J Gagne, Krista F Huybrechts, William B Feldman, Kristyn Chin, Aaron S Kesselheim
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. Drug safety 44 (7) (2021)
Vrushab Gowda, Reed F Beall, Aaron S Kesselheim, Ameet Sarpatwari
Identifying potential prescription drug product hopping. Nature biotechnology 39 (4) (2021)
Alice L Bhasale, Ameet Sarpatwari, Wendy Lipworth, Mathias Møllebaek, Eliza J McEwin, Nileesa Gautam, Adrian Santiago Ortiz, Barbara J Mintzes
Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings. British journal of clinical pharmacology (2021)
John C Messinger, Daniel J Ikeda, Ameet Sarpatwari
Civil commitment for opioid misuse: do short-term benefits outweigh long-term harms? Journal of medical ethics (2021)
Ameet Sarpatwari, Ankur Pandya, Emily P Hyle, Govind Persad
COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach? Annals of internal medicine (2021)
Anna Kaltenboeck, Maura Calsyn, Geert W J Frederix, Justin Lowenthal, David Mitchell, Bruce Rector, Ameet Sarpatwari
Grounding Value-Based Drug Pricing in Population Health. Clinical pharmacology and therapeutics 107 (6) (2020)
Alice L Bhasale, Ameet Sarpatwari, Marie Louise De Bruin, Joel R Lexchin, Ruth Lopert, Priya Bahri, Barbara J Mintzes
Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clinical pharmacology and therapeutics 109 (6) (2020)
Louise C Druedahl, Anna Birna Almarsdóttir, Sofia Kälvemark Sporrong, Marie Louise De Bruin, Hans Hoogland, Timo Minssen, Marco van de Weert, Aaron S Kesselheim, Ameet Sarpatwari
A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. Nature biotechnology 38 (11) (2020)
Seoyoung C Kim, Ameet Sarpatwari, Joan E Landon, Rishi J Desai
Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States. Arthritis & rheumatology (Hoboken, N.J.) 72 (6) (2020)
Ameet Sarpatwari, Mengdong He, Frazer A Tessema, Joshua J Gagne, Aaron S Kesselheim
Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. Drug safety 44 (3) (2020)
Ameet Sarpatwari, Aaron S Kesselheim
Reforming the Orphan Drug Act for the 21st Century. The New England journal of medicine 381 (2) (2019)
Ameet Sarpatwari, Jonathan DiBello, Marie Zakarian, Mehdi Najafzadeh, Aaron S Kesselheim
Competition and price among brand-name drugs in the same class: A systematic review of the evidence. PLoS medicine 16 (7) (2019)
Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John G Connolly, Michael A Fischer, Aaron S Kesselheim, Joshua J Gagne
Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS medicine 16 (3) (2019)
Emily H Jung, Ameet Sarpatwari, Aaron S Kesselheim, Michael S Sinha
FDA and EMA Biosimilar Approvals. Journal of general internal medicine 35 (6) (2019)